Sequential HAART in Treatment Resistant HIV-1 Infected Patients

NCT00128908 Phase 4 TERMINATED

This is an open label, crossover pilot study to explore the safety and efficacy of a rapid cycling regimen of antiretroviral combination therapy in HIV-1 infected patients with virus harboring genotypic resistance to at least three classes of antiretroviral therapy.

Details

Lead sponsor	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase	Phase 4
Status	TERMINATED
Enrolment	3
Start date	2005-09
Completion	2007-01

Conditions

• HIV Infections

Interventions

• Standard Continuous Highly Active Antiretroviral Therapy (HAART)
• Rapidly Cycled HAART

Primary outcomes

• Changes in plasma HIV-1 RNA load — 12 weeks

Countries

Netherlands